Loading...
XSHE
002317
Market cap2.70bUSD
Dec 05, Last price  
22.47CNY
1D
-2.30%
1Q
9.13%
Jan 2017
81.94%
IPO
137.72%
Name

Guangdong Zhongsheng Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002317 chart
P/E
P/S
7.74
EPS
Div Yield, %
0.89%
Shrs. gr., 5y
0.68%
Rev. gr., 5y
-0.51%
Revenues
2.47b
-5.48%
326,896,741404,403,391484,305,049551,602,812640,714,827750,643,827886,433,2231,090,027,7021,308,516,5031,577,736,5931,692,485,8231,964,235,0012,361,506,4462,531,516,4391,895,823,5602,429,095,4632,676,151,6172,610,550,1202,467,418,394
Net income
-299m
L
31,882,31742,266,10274,384,148100,354,725131,510,099150,537,489181,511,696187,702,279224,562,067296,714,725414,369,019420,121,093435,648,315317,729,4690277,631,096322,050,284263,273,179-299,157,116
CFO
338m
+77.24%
17,907,33449,354,64572,858,784100,891,08791,719,57970,555,422142,379,371110,945,083100,595,091192,248,390338,282,194369,905,148326,781,984251,155,767138,932,206622,766,28863,069,779190,613,632337,842,262
Dividend
May 23, 20240.2 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Guangdong Zhongsheng Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. The company offers Chinese and chemical medicines. It is also involved in the research and development of products in the fields of ophthalmology, cardiovascular, cerebrovascular, respiratory, digestive, diabetes, tumor, and senile degenerative diseases. The company was founded in 1979 and is based in Dongguan, China.
IPO date
Dec 11, 2009
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT